ENUM 244C8 / Palvella Therapeutics - LARVOL DELTA

Enumeral announces additional data on its novel class of PD-1 antagonist to be presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting (Businesswire) - "Enumeral Biomedical Holdings...announced that it will present research findings on the Company’s novel class of anti-PD-1 antibodies in a poster at the AACR Annual Meeting 2016 in New Orleans. Enumeral is reporting in a poster presentation at the AACR conference that Enumeral’s anti-PD-1 antibody ENUM 244C8 appears to elicit cytokine secretion from cell types associated with innate immunity in ex vivo assays using lung biopsy samples from human patients."

Preclinical • Oncology